These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29758944)

  • 1. The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
    Bhat RV; Andersson U; Andersson S; Knerr L; Bauer U; Sundgren-Andersson AK
    J Alzheimers Dis; 2018; 64(s1):S547-S554. PubMed ID: 29758944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
    Wadhwa P; Jain P; Jadhav HR
    Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase 3: a drug target for CNS therapies.
    Bhat RV; Budd Haeberlein SL; Avila J
    J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
    Gao C; Hölscher C; Liu Y; Li L
    Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3: A potential target and pending issues for treatment of Alzheimer's disease.
    Zhao J; Wei M; Guo M; Wang M; Niu H; Xu T; Zhou Y
    CNS Neurosci Ther; 2024 Jul; 30(7):e14818. PubMed ID: 38946682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
    Qu L; Li S; Ji L; Luo S; Ding M; Yin F; Wang C; Luo H; Lu D; Liu X; Peng W; Kong L; Wang X
    Eur J Med Chem; 2021 Dec; 226():113889. PubMed ID: 34649182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
    Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
    ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK3 inhibitors and disease.
    Hernández F; Nido JD; Avila J; Villanueva N
    Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
    Wagman AS; Johnson KW; Bussiere DE
    Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSK3 and tau: two convergence points in Alzheimer's disease.
    Hernandez F; Lucas JJ; Avila J
    J Alzheimers Dis; 2013; 33 Suppl 1():S141-4. PubMed ID: 22710914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.
    Georgievska B; Sandin J; Doherty J; Mörtberg A; Neelissen J; Andersson A; Gruber S; Nilsson Y; Schött P; Arvidsson PI; Hellberg S; Osswald G; Berg S; Fälting J; Bhat RV
    J Neurochem; 2013 May; 125(3):446-56. PubMed ID: 23410232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
    Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GSK3 hypothesis of Alzheimer's disease.
    Hooper C; Killick R; Lovestone S
    J Neurochem; 2008 Mar; 104(6):1433-9. PubMed ID: 18088381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK3 in Alzheimer's disease: mind the isoforms.
    Ma T
    J Alzheimers Dis; 2014; 39(4):707-10. PubMed ID: 24254703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase 3: more than a namesake.
    Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
    Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease.
    Martinez A; Perez DI; Gil C
    Curr Top Med Chem; 2013; 13(15):1808-19. PubMed ID: 23931441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.